The melanocortin system: MC1R–MC5R receptors and peptide pharmacology

Detailed explanation

The melanocortin system is a five-member G-protein-coupled receptor family (MC1R through MC5R) engaged by endogenous peptide ligands derived from post-translational processing of the proopiomelanocortin (POMC) precursor. The 267-amino-acid POMC precursor is processed by prohormone convertases in the pituitary and periphery to generate α-melanocyte-stimulating hormone (α-MSH, 13 amino acids acetylated at the N-terminus), β-MSH, γ-MSH, adrenocorticotropic hormone (ACTH, 39 amino acids), and additional peptide fragments. The various melanocortin ligands engage the five receptors with differing affinities, providing a tissue-specific signalling architecture that regulates pigmentation, appetite, sexual function, adrenal steroidogenesis, and exocrine function. Each melanocortin receptor is a class A GPCR coupled principally to Gαs/cAMP signalling, with substantial differences in tissue distribution and physiological function. MC1R is expressed prominently on melanocytes in skin and hair follicles, where activation drives eumelanin synthesis (dark pigmentation) over pheomelanin (light pigmentation); polymorphisms in MC1R (particularly the R151C, R160W, and D294H variants) are associated with red hair, fair skin, and elevated melanoma risk. MC2R is exclusive to adrenal cortex where it functions as the ACTH receptor driving cortisol synthesis — MC2R activation is what distinguishes ACTH from other melanocortins. MC3R is expressed in central nervous system and periphery with roles in energy homeostasis and inflammation. MC4R is expressed prominently in hypothalamic paraventricular and arcuate neurons where it regulates appetite, energy expenditure, and sexual function; loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset human obesity. MC5R is expressed on exocrine gland cells and has roles in sebum production and exocrine function. Endogenous α-MSH is the principal broad-spectrum agonist of MC1R, MC3R, MC4R, and MC5R (with limited MC2R activity). Endogenous agouti-related peptide (AgRP), produced by hypothalamic arcuate neurons, is the endogenous inverse agonist of MC3R and MC4R — providing bidirectional endogenous regulation of these central appetite-and-sexual-function receptors. The MC4R/AgRP balance is a critical regulator of the leptin-melanocortin pathway that integrates peripheral energy signals with central appetite control. Pharmacological engagement of the melanocortin system uses synthetic peptide agonists with varying receptor selectivity. Melanotan II (a modified cyclic heptapeptide) is a non-selective melanocortin-receptor agonist engaging MC1R (skin pigmentation), MC3R and MC4R (appetite and sexual function), and MC5R (exocrine effects). PT-141 (bremelanotide) is a Melanotan II derivative with modified peptide structure that reduces pigmentation activity while preserving the sexual-function effects mediated by central MC4R activation. Afamelanotide (Scenesse, an α-MSH analogue) is licensed for erythropoietic protoporphyria to increase eumelanin as photoprotection. Setmelanotide (Imcivree) is an MC4R-selective agonist licensed for rare genetic obesity syndromes (POMC deficiency, leptin-receptor deficiency, Bardet-Biedl syndrome). Mechanistically, MC4R activation in central sexual-function circuits drives sexual arousal and libido effects independent of vascular mechanisms — the pharmacological basis of PT-141's licensed indication for hypoactive sexual desire disorder (HSDD) in premenopausal women. This central-nervous-system mechanism is fundamentally different from the vascular mechanism of PDE5 inhibitors (sildenafil, tadalafil) which act on nitric oxide-mediated smooth muscle relaxation in erectile tissue. The two mechanisms are complementary rather than substitutive — PDE5 inhibitors address vascular erectile function; melanocortin agonists address central arousal. Standard research assays for melanocortin pharmacology include cAMP accumulation assays in receptor-expressing cell lines (HEK293 or CHO cells transfected with individual MC receptors); competitive binding studies against radiolabelled α-MSH; behavioural sexual-function assessment in rodent models; food intake and body weight measurements in appetite research; and skin pigmentation measurement (typically via melanin content or standardised photography) for MC1R-focused pigmentation research. KPV (the C-terminal Lys-Pro-Val tripeptide of α-MSH) is included on this site partly because of the melanocortin-ancestry naming but acts principally through intracellular NF-κB modulation rather than melanocortin-receptor engagement — a mechanistically important distinction.